Fresenius continues business consolidation with sale of fertility business for $545M -

A consortium consisting of KKR portfolio company IVI RMA and Spanish PE firm GED Capital agreed to pay €500 million for Eugin Group, Fresenius’ fertility business. Closing of the transaction is expected to take place in Q1 2024. Fresenius purchased the company three years ago as it sought to cash in on rising infertility rates and waning government support for fertility programs. In 2022, Eugin generated sales of $247 million. Fresenius CEO, Michael Sen, says the divestment allows the company to further prioritize and strengthen efforts to core business areas.